ERBB2 and breast cancer: Durcker et al. observed that trastuzumab treatment led to elevated levels of sEV PERP, ITB1, GNAS2, and GNA13 proteins in HER2+ and trastuzumab-sensitive BC cells, but not in the resistant cells [163].